The drug biz is abuzz over social media. It's the new frontier. For a lot of PR and corporate communications teams it's all about new media and social media. Some biopharmas, big and small, now have directors of social media. Most are still trying to find their way, but the Food and Drug Administration may soon direct them.
It's my turn. As fate would have it, on the day of Dendreon's first analyst/investor meeting in years, I have to report for jury duty this Thursday in Newark, NJ. But apparently it wouldn't have mattered if I were available anyway or wanted to send a surrogate.
When it rains, it pours. I mean, what a crazy Monday for deals and data in biopharma.
Iin light of evidence that some drug makers have gone to great lengths to turn scientific articles into marketing vehicles for their products, some influential medical editors are cracking down on industry-financed ghostwriting. And they are getting help from some members of Congress.
There! I resisted writing a blog headline that attempts some tired play on words with the Arena Pharmaceuticals' clinical trial acronyms BLOSSOM and BLOOM.
Today is the 16th annual "Newsmakers in Biotech" event put on by Thomson Reuters and BioCentury.
Tomorrow I'll be hanging out at the BioCentury/Thomson Reuters "Newsmakers in the Biotech Industry" conference in NYC, so I won't be able to monitor the webcast of an FDA panel meeting for a most intriguing drug.
Patrick Swayze is sadly a statistic. He is one of an estimated 35,000 people in the United States who will die from pancreatic cancer this year. Several companies are working on drugs for the disease, but the path is littered with failures.
Surely, Eli Lilly didn't throw it's restructuring plan together in a couple of weeks, but it was just the end of last month when Leerink Swann analyst Seamus Fernandez said LLY needed to cut costs and/or do a big deal. So, kudos to him for getting out ahead of it.
Usually when a company announces an executive departure the news comes out in a press release with a header along the lines of , "So-and-so to retire, search begins for successor," or, "XYZ Corp. CEO resigns, interim CEO appointed," etc.
After a summer of setbacks, President Barack Obama summoned Congress to enact sweeping health care legislation, declaring the "time for bickering is over" and the moment has arrived to help millions who have insurance and many more without it.
Some analysts had been telling clients recently that they thought Vivus' diet drug Qnexa could take the lead in the three-contestant race to get the next prescription diet pill on the market. But they didn't think it would take such a commanding lead.
Investors ought to get ready for a bull market, said Brian Belski, chief investment strategist at Oppenheimer & Co. and Art Nunes, market strategist at IMS Capital Management. They shared their take on the markets with investors.
Talk about a short tenure. Only eight months after Roche installed him as CEO of Genentech, Pascal Soriot is moving on (up?) to become COO of Roche's Pharma Division.
Japan's Daiwa Securities Group plans to buy out Sumitomo Mitsui Financial Group from their investment banking joint venture, a source familiar with the matter said.
G20 policymakers will this weekend promise to keep economic support packages in place until recovery is certain and seek to reassure financial markets they have credible plans to withdraw the stimulus when appropriate.
Chinese technology company Shanda Interactive Entertainment is planning to spin off its video game unit and raise as much as $800 million in a initial public offering in the United States, looking to follow in the footsteps of rival Sohu.com.
Lost in the coverage of the Pfizer-Wyeth deal that day, but nonetheless disclosed in the company's simultaneous earnings release back on January 26th of this year, PFE revealed it had taken a $2.3 billion charge for a pending settlement over marketing.
Virtually every large pharmaceutical company seems to have discovered cancer, and a substantial portion of the smaller biotechnology companies are focused on it as well. Together, the companies are pouring billions of dollars into developing cancer drugs.
Boston Scientific has rallied back to its highest levels since last year's financial crisis and is scheduled to discuss a key defibrillator trial this morning, prompting one large investor to position for a potential decline.